ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2500-Wollongong-Wollongong-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
42
trial(s) found.
NCT07728188
Haem
Phase 3
Not yet recruiting
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM) (
M22-538
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT07545356
Advanced
Phase 1
Not yet recruiting
A Phase 1 Dose-Finding and Dose Optimization-Expansion Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors (
KIVU-305-01
)
anti-CEACAM5 antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Wollongong Hospital
QLD
4999 - Unspecified - Clinical Trial Site QLD
NCT07492641
Advanced
Phase 3
Recruiting
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease (
KANDELA-302
)
CDK4/6 inhibitor
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT07455851
Haem
Phase 1 / Phase 2
Recruiting
A FIH Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
R17372-HM-2493
)
bispecific GPRC5D/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2031 - Randwick - Prince of Wales Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07291037
Advanced
Phase 3
Recruiting
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (
TROPION-Lung17
)
anti-Trop2 antibody-drug conjugate
taxane
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07284849
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (
INCA033890-303
)
anti-VEGF monoclonal antibody
bispecific TGFBR2/PD-1 antibody
Colorectal adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07259213
Radonc
Phase 1 / Phase 2
Recruiting
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-
RAD402
, a Radiolabeled Anti-Kallikrein-Related Peptidase 3 (KLK3) Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants With Castration-Resistant Prostate Cancer (CRPC)
radioconjugate,KLK3-targeting
Castrate-resistant prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07214779
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (
MAESTRA-2
)
CDK2 inhibitor
Ovarian cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT07211958
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation (
REVEAL-ND-NPM1
)
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Linear Clinical Research
NCT07197580
Radonc
Phase 3
Recruiting
A Phase 3, Randomized, Multi-Center, Open-Label Study to Compare 177Lu-TLX250 (Lutetium (177Lu) Girentuximab Tetraxetan) With the Investigator's Choice of a Single Agent Therapy in Participants With Carbonic Anhydrase 9 (CAIX) Expressing, Advanced Relapsed or Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) (
LUTEON
)
radioconjugate,CA9-targeting
Clear cell renal cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07190300
Paed
Phase 1 / Phase 2
Recruiting
TulmiSTAR-02
: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer
CYP17A1 inhibitor
EZH1/2 inhibitor
antiandrogen,nonsteroidal,second generation
Castrate-sensitive prostate cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
NCT06997497
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012) (
1084-012
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colon adenocarcinoma
Rectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06960395
Advanced
Phase 1
Recruiting
A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (
VIR-5525-V101
)
anti-PD-1 monoclonal antibody
bispecific T-cell engager,EGFR-targeting
Cancer
Cervical squamous cell carcinoma
Colorectal cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT06896916
Haem
Phase 1
Recruiting
Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma (
M24-555
)
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06830850
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (
HRS-5041-103
)
AR PROTAC degrader
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2076 - Wahroonga - Sydney Adventist Hospital
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06824155
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-
RAD202
, a Lutetium-177 Radiolabeled Single Domain Antibody Against Human Epidermal Growth Factor Receptor 2 in Patients With Advanced Solid Tumours
radioconjugate,ERBB2-targeting
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06796907
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
anti-B7H4 antibody-drug conjugate
Cancer
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06768489
Haem
Phase 1
Recruiting
A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma (
79635322MMY1002
)
anti-CD38 monoclonal antibody
immunomodulatory imide drug
trispecific T-cell engager,BCMA/GPRC5D-targeting
Multiple myeloma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
NCT06731478
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu\xAE) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (
DS8201-724
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06692738
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02) (
D702BC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06669247
Haem
Phase 1 / Phase 2
Recruiting
A First-in-Human (FIH) Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN7945, an Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
COSTIMM
)
bispecific CD38/CD28 antibody
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4217 - Benowa - Pindara Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06630806
Haem
Phase 1
Recruiting
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma (
TED18162
)
anti-GPRC5D monoclonal antibody
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
NCT06627647
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03) (
D702FC00001
)
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2500 - Wollongong - Wollongong Hospital
QLD
4215 - Southport - Gold Coast University Hospital
4812 - Hyde Park - Icon Cancer Centre Townsville
NCT06613009
Advanced
Phase 1
Recruiting
A Phase 1 Multicenter, Open-label Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer (
CIBI3009A101
)
anti-DLL3 antibody-drug conjugate
Small-cell lung cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT06520345
Radonc
Phase 3
Recruiting
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment (
177Lu-TLX591-203
)
radioconjugate,PSMA-targeting
Castrate-resistant prostate cancer
Prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3051 - Melbourne - Australian Prostate Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
WA
6150 - Murdoch - GenesisCare Murdoch
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06349408
Advanced
Phase 1
Recruiting
A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors (
CIBI3001A101
)
bispecific EGFR/B7H3 antibody-drug conjugate
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
SA
5000 - Adelaide - Cancer Research SA
NCT06345079
Advanced
Phase 2
Recruiting
A Randomised Study of Cessation of Somatostatin Analogues After Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours (
STOPNET
)
Octreotide
cancer therapy
endocrine therapy
endocrine therapy,somastatin axis-targeting
somatostatin analog
Neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06340568
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (
Fern-EC-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Endometrial cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06305962
Radonc
Phase 1
Recruiting
Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours (
177Lu-RAD204.2023.0001
)
radioconjugate,PD-L1-targeting
Cutaneous melanoma
Endometrial cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6150 - Murdoch - GenesisCare Murdoch
NCT06233942
Advanced
Phase 1
Recruiting
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (
BG-C9074-101
)
anti-B7H4 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06106945
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Multiple Myeloma (
D7230C00001
)
anti-GPRC5D antibody-drug conjugate
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05669989
Haem
Phase 2
Enrolling by invitation
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (
LTS17704
)
anti-CD38 monoclonal antibody
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05533697
Advanced
Phase 1 / Phase 2
Recruiting
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (
mRNA-4359-P101
)
mRNA personalised cancer vaccine,IDO/PD-L1-targeting
Solid tumour
NSW
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2228 - Miranda - Southside Cancer Care Centre
2500 - Wollongong - Wollongong Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05462236
Advanced
Phase 2
Recruiting
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
NCT04643002
Haem
Phase 1 / Phase 2
Recruiting
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol (
ACT16482
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT04534205
Advanced
Phase 2 / Phase 3
Recruiting
An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (
AHEAD-MERIT
)
anti-PD-1 monoclonal antibody
vaccine therapy,HPV-E6/HPV-E7-targeting
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - Adelaide - Cancer Research SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12626000026325
Advanced
Not Applicable
Not yet recruiting
Evaluating the feasibility and acceptability of Geriatric Assessment-Driven Interventions for oncology patients at Wollongong Hospital (
GAIN-Woll
)
Solid tumour
NSW
2500 - Wollongong - Wollongong Hospital
ACTRN12625000697482
Advanced
Phase 2
Recruiting
A parallel-group, 2-arm, Phase 2, multisite, stratified, double-blind, randomised, study to investigate the safety and effectiveness of doxycycline or placebo in conjunction with standard of care in adults with metastatic adenocarcinoma of the lung undergoing targeted anti-cancer therapy. (
DULCE
)
placebo
tetracycline antibiotic
Lung cancer
NT
0870 - Alice Springs, Alice Springs Hospital
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2500 - Wollongong - Wollongong Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
ACTRN12623001077651
Advanced
Phase 1 / Phase 2
Recruiting
A Modular, Multi-part, Multi-arm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of GRWD5769 Alone and in Combination with Anticancer Treatments in Patients with Solid Malignancies - Module 2. (
EMITT-1
)
ERAP1 inhibitor
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12613000358741
Haem
Phase 4
Not yet recruiting
The effect of subcutaneous azacitidine on overall survival using the alternate regimen of 75mg/m2/day for 3 days/week (Monday, Wednesday, Friday) for 2 weeks each month in elderly patients (over 65 years old) with high risk myelodysplasia/acute myeloid leukaemia.
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2217 - Kogarah - St George Hospital
2500 - Wollongong - Wollongong Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (37)
Not yet recruiting (3)
Enrolling by invitation (1)
Recruitment Country and State
NSW (42)
VIC (30)
QLD (23)
WA (17)
SA (12)
NZ (2)
ACT (1)
NT (1)
Phase
Phase 1 (11)
Phase 1 / Phase 2 (9)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (14)
Phase 4 (1)
Trial Type
Advanced (24)
Haem (12)
Radonc (5)
Paed (1)
Cancer Therapy Class
PD-1/PD-L1
33%
PD-1
29%
cereblon
17%
BCMA
14%
CD38
14%
VEGF
12%
AR
7%
androgen axis
7%
EGFR
7%
ERBB2
7%
PD-L1
7%
GPRC5D
7%
proteasome
5%
CYP17A1
5%
B7H4
5%
CTLA4
5%
TIGIT
5%
CEACAM5
2%
CDK4
2%
CDK4 selective
2%
CDK6
2%
oestrogen axis
2%
Trop2
2%
TGFBR2
2%
KLK3
2%
CDK2
2%
KMT2A
2%
menin-MLL1
2%
menin
2%
EZH1
2%
EZH2
2%
KRAS
2%
CD28
2%
DLL3
2%
PSMA
2%
B7H3
2%
somastatin axis
2%
IDO
2%
MNK
2%
CD47
2%
IL-2
2%
ROCK2
2%
TGF-beta
2%
HPV-E6
2%
HPV-E7
2%
ERAP1
2%
DNA methyltransferase
2%
Facility
2500 - Wollongong - Wollongong Hospital (42)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
3004 - Melbourne, Southbank - Alfred Health (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3168 - Clayton - Monash Medical Centre (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
4215 - Southport - Gold Coast University Hospital (4)
5000 - Adelaide - Cancer Research SA (4)
3121 - Richmond - Epworth Freemasons Hospital (3)
4217 - Benowa - Pindara Private Hospital (3)
2170 - Liverpool - Liverpool Hospital (3)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
3021 - St Albans - Western Health - Sunshine Hospital (3)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
4812 - Hyde Park - Icon Cancer Centre Townsville (3)
2109 - North Ryde - Macquarie University Hospital (3)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (3)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (3)
6150 - Murdoch - GenesisCare Murdoch (3)
5042 - Bedford Park - Flinders Medical Centre (3)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - One Clinical Research (2)
2031 - Randwick - Prince of Wales Hospital (2)
2217 - Kogarah - St George Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
5011 - Woodville South - The Queen Elizabeth Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2541 - Nowra - Shoalhaven District Memorial Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4999 - Unspecified - Clinical Trial Site QLD (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2605 - Garran - The Canberra Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
6009 - Nedlands - Hollywood Private Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (1)
3002 - East Melbourne - Epworth Freemasons (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
3051 - Melbourne - Australian Prostate Centre (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
NA
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
2228 - Miranda - Southside Cancer Care Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
0870 - Alice Springs, Alice Springs Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Thoracic cancer
Lung cancer
Respiratory tract cancer
Gastrointestinal cancer
Non-small cell lung cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
Gynaecological cancer
Colorectal adenocarcinoma
Castrate-resistant prostate cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Breast cancer
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Endometrial cancer
Ovarian cancer
Clear cell renal cell carcinoma
Kidney cancer
Castrate-sensitive prostate cancer
Colon adenocarcinoma
Rectal adenocarcinoma
Cervical cancer
Cervical squamous cell carcinoma
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
Non-squamous non-small-cell lung cancer
Neuroendocrine tumour
Breast adenocarcinoma
Cutaneous melanoma
Melanoma
Skin cancer
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy